Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
11.19
+5.37 (92.27%)
At close: Nov 20, 2024, 4:00 PM
11.50
+0.31 (2.77%)
Pre-market: Nov 21, 2024, 4:48 AM EST
Company Description
Exicure, Inc. does not have significant operations.
previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Paul Kang |
Contact Details
Address: 2430 North Halsted Street Chicago, Illinois 60614 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M2008 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Kang | Chief Executive Officer, President and Director |
| Jiyoung Hwang | Chief Financial Officer, Secretary and Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 8-K | Current Report |
| Sep 16, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 13, 2024 | 8-K | Current Report |
| Aug 26, 2024 | 8-K | Current Report |
| Aug 19, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |